MedPath

An Evaluation of an Injectable Material for Correction of Wrinkles

Phase 3
Withdrawn
Conditions
Jowls
Interventions
Device: Calcium Hydroxylapatite injection
Registration Number
NCT00510081
Lead Sponsor
Northwestern University
Brief Summary

The objective of this study is to determine the effectiveness of a filler in improving wrinkles.

Detailed Description

The primary objective of this study is to determine whether focal injection of calcium hydroxylapatite (Radiesse®), an injectable biodegradable filler, into jowl-induced chin notches can result in safe, aesthetically pleasing, and long-lasting correction of these.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Age 40-65
  • Have wrinkles
  • The subjects are in good health.
  • The subject has willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator.
Exclusion Criteria
  • Subjects who have received within the past 3 months or are planning to receive in the next 6 months, botulinum toxin injections for correction of wrinkles.
  • Subjects who have received within the past one year any soft tissue augmentation material into the chin and experimental area (defined as any area on the face below the lower lip vermilion, excluding the lateral lip marionette line up to 1 cm below this level).
  • Subjects with prior history of nodule formation or hypersensitivity reactions to lidocaine or medium-term augmentation materials, including hyaluronic acid derivatives, poly-L-lactic acid, and calcium hydroxylapatite.
  • Subjects who are currently using anticoagulation therapy.
  • Subjects who have a history of bleeding disorders.
  • Subjects who are unable to understand the protocol or to give informed consent.
  • Subjects with mental illness.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1Calcium Hydroxylapatite injectionsubjects will receive filler injections
Primary Outcome Measures
NameTimeMethod
Correction of wrinkles1 week
Secondary Outcome Measures
NameTimeMethod
Development of adverse events1 week
© Copyright 2025. All Rights Reserved by MedPath